eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study

Sorafenib may reduce endothelial nitric oxide synthase (eNOS) activity by inhibiting vascular endothelial growth factor receptors (VEGF-R), leading to a decrease in nitric oxide production. In the Italian multicenter ePHAS (eNOS polymorphisms in HCC and sorafenib) study, we analyzed the role of eNOS...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Gardini, Andrea Casadei, Marisi, Giorgia, Faloppi, Luca, Scarpi, Emanuela, Foschi, Francesco Giuseppe, Iavarone, Massimo, Lauletta, Gianfranco, Corbelli, Jody, Valgiusti, Martina, Facchetti, Floriana, Corte, Cristina della, Neri, Luca Maria, Tamberi, Stefano, Cascinu, Stefano, Scartozzi, Mario, Amadori, Dino, Nanni, Oriana, Tenti, Elena, Ulivi, Paola, Frassineti, Giovanni Luca
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2016
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5053704/
https://ncbi.nlm.nih.gov/pubmed/27058899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8569
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы